Diffusion-weighted Imaging Versus Contrast-enhanced MR Imaging for the Differentiation of Renal Oncocytomas and Chromophobe Renal Cell Carcinomas

Overview

Journal Eur Radiol

Specialty Radiology

Date 2017 Jun 21

PMID 28631081

Citations 13

Authors

Yan Zhong

Haiyi Wang

Yanguang Shen

Aitao Guo

Jia Wang

Suhai Kang

Lu Ma

Jingjing Pan

Huiyi Ye

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare the performance of diffusion-weighted imaging (DWI) with that of contrast-enhanced MRI in differentiating renal oncocytomas from chromophobe renal cell carcinomas (RCCs).

Methods: We recruited 48 patients with histopathologically confirmed renal oncocytomas (n=16) and chromophobe RCCs (n=32). All patients underwent preoperative DWI and contrast-enhanced MRI. Apparent diffusion coefficient (ADC) and signal intensity were measured in each patient. ADC ratio and percentage of signal intensity change were calculated.

Results: Mean ADC values for renal oncoctytomas were significantly higher than those for chromophobe RCCs (1.59±0.21 vs. 1.09±0.29× 10 mm/s, p < 0.001). Area under the ROC curve, sensitivity and specificity were 0.931, 87.5% and 84.4%, respectively, for ADC measurement of DW imaging; 0.825, 87.5% and 75%, respectively, for enhancement ratio (p > 0.05). Adding ADC values to the enhancement ratios in the ROC, analysis to differentiate renal oncocytoma from chromophobe RCCs increased specificity from 75 to 87.5% at 87.5% sensitivity without significantly increasing the AUC (0.930).

Conclusions: Both DWI and contrast-enhanced MRI may assist in differentiating renal oncocytomas from chromophobe RCCs, with DWI showing higher diagnostic value. The combination of the two parameters could potentially provide better performance in distinguishing these two tumours.

Key Points: • ADC values can assist in differentiating renal oncocytomas from chromophobe RCCs. • DW imaging possesses better specificity than does contrast-enhanced MR imaging. • Combining the two parameters provides higher specificity regarding the differential diagnosis.

Citing Articles

Comparison of conventional diffusion-weighted imaging and intravoxel incoherent motion in differentiating between chromophobe renal cell carcinoma and renal oncocytoma: a preliminary study.

Zhu Q, Sun J, Ye J, Zhu W, Chen W Br J Radiol. 2024; 97(1158):1146-1152.

PMID: 38688580 PMC: 11135799. DOI: 10.1093/bjr/tqae088.

Four-phase computed tomography helps differentiation of renal oncocytoma with central hypodense areas from clear cell renal cell carcinoma.

Qu J, Jiang H, Song X, Wu J, Ma H Diagn Interv Radiol. 2023; 29(2):205-211.

PMID: 36960636 PMC: 10679699. DOI: 10.5152/dir.2022.21834.

Whole-Lesion CT Texture Analysis as a Quantitative Biomarker for the Identification of Homogeneous Renal Tumors.

Meng X, Li S, Feng C, Hu D, Li Z, Niu Y Life (Basel). 2022; 12(12).

PMID: 36556513 PMC: 9781849. DOI: 10.3390/life12122148.

Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.

Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I Diagnostics (Basel). 2022; 12(4).

PMID: 35453866 PMC: 9029773. DOI: 10.3390/diagnostics12040817.

Capability of intravoxel incoherent motion and diffusion tensor imaging to detect early kidney injury in type 2 diabetes.

Zhang H, Wang P, Shi D, Yao X, Li Y, Liu X Eur Radiol. 2022; 32(5):2988-2997.

PMID: 35031840 DOI: 10.1007/s00330-021-08415-6.

References

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M . EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67(5):913-24. DOI: 10.1016/j.eururo.2015.01.005. View

Haifler M, Kutikov A . Current Role of Renal Biopsy in Urologic Practice. Urol Clin North Am. 2017; 44(2):203-211. DOI: 10.1016/j.ucl.2016.12.006. View

Oxley J, Sullivan J, Mitchelmore A, Gillatt D . Metastatic renal oncocytoma. J Clin Pathol. 2007; 60(6):720-2. PMC: 1955059. DOI: 10.1136/jcp.2006.044198. View

Hotker A, Mazaheri Y, Wibmer A, Zheng J, Moskowitz C, Tickoo S . Use of DWI in the Differentiation of Renal Cortical Tumors. AJR Am J Roentgenol. 2015; 206(1):100-5. PMC: 4826468. DOI: 10.2214/AJR.14.13923. View

Lei Y, Wang H, Li H, Rao Y, Liu J, Tian S . Diagnostic Significance of Diffusion-Weighted MRI in Renal Cancer. Biomed Res Int. 2015; 2015:172165. PMC: 4430628. DOI: 10.1155/2015/172165. View

Ishigami K, Jones A, Dahmoush L, Leite L, Pakalniskis M, Barloon T . Imaging spectrum of renal oncocytomas: a pictorial review with pathologic correlation. Insights Imaging. 2014; 6(1):53-64. PMC: 4330236. DOI: 10.1007/s13244-014-0373-x. View

Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas F, Klingler H . Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. Eur J Radiol. 2014; 83(6):909-913. DOI: 10.1016/j.ejrad.2014.02.026. View

Schieda N, Al-Subhi M, Flood T, El-Khodary M, McInnes M . Diagnostic accuracy of segmental enhancement inversion for the diagnosis of renal oncocytoma using biphasic computed tomography (CT) and multiphase contrast-enhanced magnetic resonance imaging (MRI). Eur Radiol. 2014; 24(11):2787-94. DOI: 10.1007/s00330-014-3310-y. View

Eshed I, Elias S, Sidi A . Diagnostic value of CT-guided biopsy of indeterminate renal masses. Clin Radiol. 2004; 59(3):262-7. DOI: 10.1016/j.crad.2003.09.022. View

10.

Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View

11.

Wang H, Cheng L, Zhang X, Wang D, Guo A, Gao Y . Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology. 2010; 257(1):135-43. DOI: 10.1148/radiol.10092396. View

12.

Zhang J, Tehrani Y, Wang L, Ishill N, Schwartz L, Hricak H . Renal masses: characterization with diffusion-weighted MR imaging--a preliminary experience. Radiology. 2008; 247(2):458-64. DOI: 10.1148/radiol.2472070823. View

13.

Squillaci E, Manenti G, Cova M, Di Roma M, Miano R, Palmieri G . Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res. 2005; 24(6):4175-9. View

14.

Snyder M, Bach A, Kattan M, Raj G, Reuter V, Russo P . Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006; 176(6 Pt 1):2391-5. DOI: 10.1016/j.juro.2006.08.013. View

15.

Goya C, Hamidi C, Bozkurt Y, Yavuz A, Kuday S, Gumus H . The Role of Apparent Diffusion Coefficient Quantification in Differentiating Benign and Malignant Renal Masses by 3 Tesla Magnetic Resonance Imaging. Balkan Med J. 2015; 32(3):273-8. PMC: 4497693. DOI: 10.5152/balkanmedj.2015.15475. View

16.

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z . 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49(5):798-805. DOI: 10.1016/j.eururo.2005.11.035. View

17.

Sun M, Ngo L, Genega E, Atkins M, Finn M, Rofsky N . Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology. 2009; 250(3):793-802. DOI: 10.1148/radiol.2503080995. View

18.

Cornelis F, Tricaud E, Lasserre A, Petitpierre F, Bernhard J, Le Bras Y . Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. Eur Radiol. 2014; 24(5):1068-80. DOI: 10.1007/s00330-014-3107-z. View

19.

Marszalek M, Ponholzer A, Brossner C, Wachter J, Maier U, Madersbacher S . Elective open nephron-sparing surgery for renal masses: single-center experience with 129 consecutive patients. Urology. 2004; 64(1):38-42. DOI: 10.1016/j.urology.2004.02.007. View

20.

Goyal A, Sharma R, Bhalla A, Gamanagatti S, Seth A, Iyer V . Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype. Acta Radiol. 2012; 53(3):349-58. DOI: 10.1258/ar.2011.110415. View